Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

177
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
177
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

124
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
124
Censoring Survival Data01:09

Censoring Survival Data

85
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
85
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

133
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
133
Truncation in Survival Analysis01:09

Truncation in Survival Analysis

201
Truncation in survival analysis refers to the exclusion of individuals or events from the dataset based on specific criteria related to the time of the event. This exclusion can happen in two primary forms: left truncation and right truncation.
Left truncation occurs when individuals who experienced the event of interest before a certain time are not included in the study. This is often due to a "delayed entry" into the study where only those who survive until a certain entry point are...
201
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

221
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
221

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

JCO oncology practice·2026
Same author

Cancer chemo-immunotherapy: time will tell.

Cancer immunology research·2026
Same author

[211At]Astatine-Based Conditioning with a Humanized CD45 Antibody for Autologous Hematopoietic Stem Cell Gene Therapy.

Blood·2026
Same author

A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results.

Journal of gynecologic oncology·2026
Same author

Chronic myeloid leukaemia: have basophils gone the way of the Dodo bird?

Leukemia·2026
Same author

Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609).

Journal for immunotherapy of cancer·2026

Related Experiment Video

Updated: Jun 26, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.5K

Avoiding Delays in Reporting Time-to-Event Randomized Trials: Calendar Backstops and Other Approaches.

Megan Othus1, Boris Freidlin2, Edward L Korn2

  • 1SWOG Cancer Research Network and Fred Hutchinson Cancer Research Center, Seattle, WA.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|May 17, 2024
PubMed
Summary
This summary is machine-generated.

New oncology treatments are extending patient survival, complicating clinical trial designs. A new backstop rule for time-to-event analyses can help manage trial conduct and data release for oncology trials.

More Related Videos

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

7.1K
Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation
09:42

Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation

Published on: November 8, 2013

13.6K

Related Experiment Videos

Last Updated: Jun 26, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.5K
Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

7.1K
Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation
09:42

Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation

Published on: November 8, 2013

13.6K

Area of Science:

  • Oncology
  • Clinical Trial Design
  • Biostatistics

Background:

  • Advancements in oncology therapies have significantly improved patient survival, leading to longer follow-up periods.
  • Traditional clinical trial designs face challenges in event-based analyses due to extended patient survival and delayed outcome data release.
  • The increasing efficacy of cancer treatments necessitates adaptive strategies for clinical trial conduct.

Purpose of the Study:

  • To propose and evaluate a prespecified backstop rule for time-to-event analyses in oncology clinical trials.
  • To address challenges in clinical trial design and conduct arising from prolonged patient survival.
  • To provide practical recommendations for implementing the proposed rule in various oncology trial settings.

Main Methods:

  • Development of a straightforward, prespecified backstop rule for time-to-event analyses.
  • Evaluation of the rule's impact using both simulated clinical trial data.
  • Assessment of the rule's performance with real-world oncology trial data.

Main Results:

  • The proposed backstop rule offers a viable solution for managing event-based analyses in oncology trials with extended survival.
  • Simulated and real-world data analyses demonstrate the rule's effectiveness in optimizing trial conduct and data timeliness.
  • The rule helps mitigate delays in outcome data release, crucial for timely therapeutic advancements.

Conclusions:

  • The prespecified backstop rule is a valuable tool for improving the design and conduct of oncology clinical trials.
  • Implementing this rule can enhance the efficiency of evaluating new oncology therapies.
  • Recommendations are provided for the broad application of this rule across diverse oncology clinical trial scenarios.